It has taken 18 years for India to produce its own affordable version to tackle the country’s second-biggest cause of cancer deaths among women
It is a Wednesday morning and Sneha Neurgaonkar sits on a gurney in a private hospital in Pune, India. The 14-year-old is at the Lalwani mother and child care hospital to receive the first Indian-made human papillomavirus (HPV) vaccine, which prevents cervical cancer.
Unlike the 10-year-old girl who was given the vaccine before her, Sneha knows what cervical cancer is and the damage it is doing to women in her country.
＼ 最新情報をチェック ／
